ライフサイエンスコーパス: acute graft-versus-host disease

1 showed similar incidences of grades II to IV acute graft-versus host disease.

2 dex (EASIX) was shown to predict death after acute graft-versus-host disease.

3 cell source and donor type, age and grade of acute graft-versus-host disease.

4 53 patients (17%) developed grades II to IV acute graft-versus-host disease.

5 ently in the treatment of steroid-refractory acute graft-versus-host disease.

6 a systemic bacterial infection, colitis, and acute graft-versus-host disease.

7 f the five children had grade II, III, or IV acute graft-versus-host disease.

8 patibility complex barriers without inducing acute graft-versus-host disease.

9 monia syndrome-like phenotype and aggravated acute graft-versus-host disease.

10 associated with a higher risk of developing acute graft-versus-host disease.

11 nd death (P = 0.002), but a similar risk for acute graft-versus-host disease.

12 ficantly increased risk of graft failure and acute graft versus host disease after URD BMT.

13 These populations correlate with acute graft-versus-host disease after allogeneic hematop

14 New-onset acute graft-versus-host disease after CAR T-cell infusio

15 There was no de novo acute graft-versus-host disease after infusion, and inci

16 (AT) was capable of protecting animals from acute graft-versus-host disease (aGVHD) across major his

17 Patients who develop steroid-refractory acute graft-versus-host disease (aGVHD) after allogeneic

18 R-181a expression in donor T cells may alter acute graft-versus-host disease (aGvHD) after allogeneic

19 Acute graft-versus-host disease (aGVHD) continues to be

20 pients were followed for disease relapse and acute graft-versus-host disease (aGvHD) development post

21 e lower incidence and severity of high-grade acute graft-versus-host disease (aGVHD) exhibited by UCB

22 arly diagnosis, prevention, and treatment of acute graft-versus-host disease (aGVHD) have been transl

23 Acute graft-versus-host disease (aGVHD) hinders the effi

24 T cells have improved survival and decreased acute graft-versus-host disease (aGVHD) in 2 different m

25 During acute graft-versus-host disease (aGVHD) in mice, autorea

26 eg cells protects recipient mice from lethal acute graft-versus-host disease (aGVHD) induced by donor

27 ective therapy for hematologic malignancies, acute graft-versus-host disease (aGVHD) is a leading cau

28 Steroid refractory gastrointestinal (GI) acute graft-versus-host disease (aGVHD) is a major cause

29 Acute graft-versus-host disease (aGVHD) is a major cause

30 Acute graft-versus-host disease (aGVHD) is a major compl

31 Acute graft-versus-host disease (aGVHD) is associated wi

32 We found that acute graft-versus-host disease (aGVHD) is associated wi

33 Acute graft-versus-host disease (aGVHD) is still a major

34 Acute graft-versus-host disease (aGVHD) is the leading c

35 Acute graft-versus-host disease (aGVHD) is the main comp

36 Acute graft-versus-host disease (aGVHD) is the most comm

37 Acute graft-versus-host disease (aGVHD) is the primary l

38 Grades II to IV acute graft-versus-host disease (aGvHD) occurred in 31%.

39 Development of acute graft-versus-host disease (aGVHD) predisposes to c

40 ty and mortality from clinically significant acute graft-versus-host disease (aGVHD) remains a limita

41 Acute graft-versus-host disease (aGVHD) remains a major

42 Acute graft-versus-host disease (aGVHD) remains a seriou

43 elopment of severe and/or steroid-refractory acute graft-versus-host disease (aGVHD) remains a signif

44 helial adhesion molecule induction in murine acute graft-versus-host disease (aGVHD) revealed unexpec

45 ly reported that dermal papillary vessels in acute graft-versus-host disease (aGVHD) support shear-re

46 The incidence of acute graft-versus-host disease (aGVHD) was compared in

47 OS), cumulative incidence of engraftment and acute graft-versus-host disease (aGVHD) within the first

48 geneic hematopoietic cell transplantation is acute graft-versus-host disease (aGVHD), a devastating c

49 lantation viral reactivation, grade II to IV acute graft-versus-host disease (aGvHD), and chronic gra

50 In acute graft-versus-host disease (aGVHD), donor T cells a

51 conditioning (with vs. without irradiation), acute graft-versus-host disease (aGVHD), or chronic graf

52 epithelium and may play a role in triggering acute graft-versus-host disease (aGVHD).

53 em cell transplantation (HSCT) is limited by acute graft-versus-host disease (aGvHD).

54 25 immunotoxin (IT) is a strategy to prevent acute graft-versus-host disease (aGvHD).

55 ed for treatment of autoimmune disorders and acute graft-versus-host disease (aGVHD).

56 CD25+ regulatory T cells (Treg cells) reduce acute graft-versus-host disease (aGvHD).

57 nstitution with complications of relapse and acute graft-versus-host disease (aGVHD).

58 atient mixed lymphocyte reactions (MLRs) and acute graft-versus-host disease (aGVHD).

59 alpha) are implicated in the pathogenesis of acute graft-versus-host disease (aGVHD).

60 d suppressor cells (MDSCs) in the setting of acute graft-versus-host disease (aGVHD).

61 which is connected to a higher incidence of acute graft-versus-host disease (aGVHD).

62 xenograft models and efficacy in preventing acute graft-versus-host disease (aGVHD).

63 thymus in mice that had previously developed acute graft-versus-host-disease (aGVHD).

64 5% CI, 1.50-5.55; P = 0.002) and grade II-IV acute graft-versus-host disease (aHR, 1.59; 95% CI, 1.06

65 ster myeloid and platelet recovery and lower acute graft versus host disease and may reduce the total

66 fied according to the presence or absence of acute graft-versus-host disease and CMV DNA in plasma.

67 suggest a novel mechanism explaining reduced acute graft-versus-host disease and improvement in autoi

68 nuated clinical symptoms in animal models of acute graft-versus-host disease and multiple sclerosis.

69 er transplant-related complications, such as acute graft-versus-host disease and opportunistic infect

70 or CMV reactivation, including patients with acute graft-versus-host disease and those receiving ster

71 One patient developed acute graft-versus-host disease and two chronic graft-ve

72 l transplantation without steroid-refractory acute graft-versus-host disease and without early relaps

73 , whereas infection, veno-occlusive disease, acute graft-versus-host disease, and death were predicte

74 One patient (5%) experienced grade 2 acute graft-versus-host disease, and no patients experie

75 cumulative incidence of grade II, III, or IV acute graft-versus-host disease at 100 days was 64 perce

76 Active acute graft-versus-host disease at TMA diagnosis was the

77 spital stay; intensive care unit admissions; acute graft-versus-host disease; Bearman toxicity score;

78 ith a naive phenotype in patients developing acute graft-versus-host disease, compared with tolerant

79 om a skin biopsy of a patient suffering from acute graft-versus-host disease following sex-mismatched

80 nig and colleagues1 demonstrate in mice that acute graft-versus-host disease (GHVD) results in a mark

81 ity (cytopenias) was reported in 4 patients, acute graft-versus-host disease grade 1 in 2, grade 2 in

82 Acute graft-versus-host disease (grade II, III, or IV) d

83 Day 100 cumulative incidences of acute graft-versus-host disease grades B to D and C to D

84 Acute graft-versus-host disease grades II to III occurre

85 Seven patients developed acute graft versus host disease (GVHD) (5 grade I-II, 2

86 Lower incidence and severity of acute graft versus host disease (GVHD) has been observed

87 ich they influence disease processes such as acute graft versus host disease (GVHD), which is the mai

88 all recipients expired by day 40 from severe acute graft versus host disease (GVHD).

89 fference in the incidence of grades II to IV acute graft versus host disease (GVHD).

90 sis was greater in patients with grade II-IV acute graft-versus-host disease (GVHD) (33.9% +/- 11.3%)

91 V (60% vs 24%, P = .01) and grades III to IV acute graft-versus-host disease (GVHD) (47% vs 14%, P =

92 ce of neutrophil recovery at day 60 was 91%, acute graft-versus-host disease (GVHD) (grade II-IV) at

93 associated with an increased probability of acute graft-versus-host disease (GVHD) (P = .02).

94 Acute graft-versus-host disease (GVHD) afflicts as much

95 lls (DC) are important in the development of acute graft-versus-host disease (GVHD) after allogeneic

96 10RB) gene with development of grades III-IV acute graft-versus-host disease (GVHD) after allogeneic

97 (BMT) recipients are at heightened risk for acute graft-versus-host disease (GVHD) after allogeneic

98 ompatibility antigen HA-1 is associated with acute graft-versus-host disease (GVHD) after allogeneic

99 us antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoiet

100 rriage correlates with increased severity of acute graft-versus-host disease (GVHD) after matched unr

101 tat) is safe and results in low incidence of acute graft-versus-host disease (GVHD) after reduced-int

102 Eight patients experienced grade I/II acute graft-versus-host disease (GVHD) after transplanta

103 o percent of patients developed grade 2 to 4 acute graft-versus-host disease (GVHD) and 74% extensive

104 the recipient is associated with less severe acute graft-versus-host disease (GVHD) and a lower risk

105 f T-bet and IFN-gamma in T cell responses in acute graft-versus-host disease (GVHD) and found that T-

106 factor, was tested for potential benefits on acute graft-versus-host disease (GVHD) and hematopoietic

107 There exists a strong association between acute graft-versus-host disease (GVHD) and IPS, and bron

108 Acute graft-versus-host disease (GVHD) and leukemic rela

109 Acute graft-versus-host disease (GVHD) and leukemic rela

110 Acute graft-versus-host disease (GVHD) and leukemic rela

111 0, SCD) had slower neutrophil recovery, less acute graft-versus-host disease (GVHD) and none had exte

112 The 6-month probabilities of grade 3 or 4 acute graft-versus-host disease (GVHD) and nonrelapse mo

113 prognostic information about development of acute graft-versus-host disease (GVHD) and subsequent mo

114 , Cav-1(-/-)donor T cells caused less severe acute graft-versus-host disease (GVHD) and yielded highe

115 Algorithms for grading acute graft-versus-host disease (GVHD) are inaccurate in

116 ates, kinetics of engraftment, toxicity, and acute graft-versus-host disease (GVHD) associated with a

117 The incidence of grade II-IV acute graft-versus-host disease (GVHD) at 100 days was 9

118 Cumulative incidences of grades 3 to 4 acute graft-versus-host disease (GVHD) at 6 months were

119 The cumulative incidence of grade 2 to 4 acute graft-versus-host disease (GVHD) at day 100 was 44

120 Acute graft-versus-host disease (GVHD) can affect the ce

121 Acute graft-versus-host disease (GVHD) causes substantia

122 e alloantigen-driven parent-into F1 model of acute graft-versus-host disease (GVHD) characterized by

123 t 4-fold lower in patients with grade 2 to 4 acute graft-versus-host disease (GVHD) compared with pat

124 Acute graft-versus-host disease (GVHD) complicated UDLI

125 Acute graft-versus-host disease (GVHD) considerably limi

126 Acute graft-versus-host disease (GVHD) developed in 18 p

127 Grade III/IV acute graft-versus-host disease (GVHD) developed in 33%

128 Acute graft-versus-host disease (GVHD) developed in 37%

129 o 100 in patients in whom grade 2 or greater acute graft-versus-host disease (GVHD) developed.

130 er induction chemotherapy and the absence of acute graft-versus-host disease (GVHD) development follo

131 10-fold higher dose of transplanted T cells, acute graft-versus-host disease (GVHD) does not develop

132 Five of 9 transplant recipients experienced acute graft-versus-host disease (GVHD) following aNK-DLI

133 Risks of acute graft-versus-host disease (GVHD) grade 2 to 4 (haz

134 Cumulative incidence (day +90) of acute graft-versus-host disease (GVHD) grade 2-4 was 21%

135 Acute graft-versus-host disease (GvHD) grade II to IV oc

136 Acute graft-versus-host disease (GVHD) grades 2 through

137 Acute graft-versus-host disease (GVHD) grades 2-4 was mo

138 DC was associated with acute graft-versus-host disease (GVHD) grades II to IV f

139 Acute graft-versus-host disease (GVHD) grades II to IV w

140 Treatment of acute graft-versus-host disease (GVHD) has evolved from

141 Treatment for steroid-resistant acute graft-versus-host disease (GVHD) has had limited s

142 nal role of Th17 cells in the development of acute graft-versus-host disease (GVHD) has not been well

143 as second-line therapy for the treatment of acute graft-versus-host disease (GVHD) in 21 patients (1

144 ood, Shah et al describe the onset of severe acute graft-versus-host disease (GVHD) in 5 of 9 patient

145 e (GF) occurred in 26 patients (16%), severe acute graft-versus-host disease (GVHD) in 9 (6%), and ch

146 nterleukin-18 (IL-18) regulates experimental acute graft-versus-host disease (GVHD) in a Fas-dependen

147 bone marrow transplantation (BMT) attenuates acute graft-versus-host disease (GVHD) in a lethally irr

148 O T cells also mediated accelerated onset of acute graft-versus-host disease (GVHD) in a murine model

149 To prevent the development of acute graft-versus-host disease (GVHD) in lethally irrad

150 ory T cells (Tregs) has been used to prevent acute graft-versus-host disease (GVHD) in mice and has s

151 in vitro and whether those cells can inhibit acute graft-versus-host disease (GVHD) in vivo upon adop

152 Acute graft-versus-host disease (GVHD) increased the ris

153 We have shown that under acute graft-versus-host disease (GVHD) inflammatory cond

154 Acute graft-versus-host disease (GVHD) is a common compl

155 Acute graft-versus-host disease (GvHD) is a complex proc

156 Acute graft-versus-host disease (GVHD) is a considerable

157 Acute graft-versus-host disease (GVHD) is a frequent com

158 Acute graft-versus-host disease (GvHD) is a life-threate

159 Acute graft-versus-host disease (GVHD) is a life-threate

160 Acute graft-versus-host disease (GvHD) is a major cause

161 Acute graft-versus-host disease (GvHD) is a major compli

162 Acute graft-versus-host disease (GVHD) is a major compli

163 Acute graft-versus-host disease (GvHD) is a major compli

164 Acute graft-versus-host disease (GvHD) is a serious comp

165 Acute graft-versus-host disease (GvHD) is an uncommon bu

166 revious experimental studies have shown that acute graft-versus-host disease (GVHD) is associated wit

167 The standard initial therapy for acute graft-versus-host disease (GVHD) is corticosteroid

168 SP) and methotrexate (MTX), the incidence of acute graft-versus-host disease (GVHD) is greater than 7

169 The risk of acute graft-versus-host disease (GVHD) is higher after a

170 Acute graft-versus-host disease (GVHD) is induced by all

171 Acute graft-versus-host disease (GVHD) is initially trig

172 an important secondary lymphoid organ where acute graft-versus-host disease (GVHD) is initiated by d

173 complication of solid organ transplantation, acute graft-versus-host disease (GVHD) is most associate

174 reased numbers of T cells in the PBSC graft, acute graft-versus-host disease (GVHD) is not increased.

175 Acute graft-versus-host disease (GVHD) is the primary li

176 Acute graft-versus-host disease (GVHD) is thought to der

177 Morbidity from acute graft-versus-host disease (GVHD) limits the succes

178 Acute graft-versus-host disease (GVHD) limits the succes

179 vivo TIP had a protective effect in a mouse acute graft-versus-host disease (GVHD) model.

180 Acute graft-versus-host disease (GVHD) occurred in 11 (1

181 Grade 3 to 4 acute graft-versus-host disease (GVHD) occurred in 20% o

182 Grades II to IV acute graft-versus-host disease (GVHD) occurred in 41% o

183 Grades II to III acute graft-versus-host disease (GVHD) occurred in 47% o

184 Gastrointestinal acute graft-versus-host disease (GVHD) occurring after a

185 Grades 2-4 acute graft-versus-host disease (GVHD) occurs in approxi

186 Acute graft-versus-host disease (GVHD) occurs less frequ

187 The relative risk (RR) of acute graft-versus-host disease (GVHD) of grades II to I

188 Acute graft-versus-host disease (GVHD) of the gastrointe

189 ssociations between MPA pharmacokinetics and acute graft-versus-host disease (GVHD) or relapse.

190 marker-based tools may identify a lower-risk acute graft-versus-host disease (GVHD) population amenab

191 g trial, 27 patients with steroid-refractory acute graft-versus-host disease (GVHD) received ABX-CBL

192 Acute graft-versus-host disease (GVHD) remains a barrier

193 sttransplantation immunosuppressive therapy, acute graft-versus-host disease (GVHD) remains a major c

194 Acute graft-versus-host disease (GVHD) remains a major l

195 Acute graft-versus-host disease (GVHD) remains a major o

196 Acute graft-versus-host disease (GVHD) remains a signifi

197 Acute graft-versus-host disease (GVHD) remains a signifi

198 Treatment of steroid-resistant acute graft-versus-host disease (GVHD) remains an unmet

199 Infections and acute graft-versus-host disease (GvHD) represent major c

200 Acute graft-versus-host disease (GVHD) results from the

201 on, specifically whether prophylaxis through acute graft-versus-host disease (GVHD) results in improv

202 Acute graft-versus-host disease (GVHD) significantly lim

203 ciating graft-versus-tumor (GVT) effect from acute graft-versus-host disease (GVHD) still remains a g

204 nal signature of T cells during breakthrough acute graft-versus-host disease (GVHD) that occurs in th

205 The optimal primary endpoint for acute graft-versus-host disease (GVHD) therapeutic trial

206 omarkers are associated with the response of acute graft-versus-host disease (GVHD) to therapy after

207 Grades II to IV acute graft-versus-host disease (GVHD) was associated wi

208 Acute graft-versus-host disease (GVHD) was more likely t

209 Grade 2 to 4 acute graft-versus-host disease (GVHD) was significantly

210 Further, the incidence of grades III to IV acute graft-versus-host disease (GVHD) was significantly

211 cumulative incidences of grades 2, 3, and 4 acute graft-versus-host disease (GVHD) were 38%, 9%, and

212 , 17 patients with glucocorticoid-refractory acute graft-versus-host disease (GVHD) were enrolled in

213 ere confirmed in vivo using a mouse model of acute graft-versus-host disease (GVHD) wherein host DCs

214 We hypothesized that initial treatment of acute graft-versus-host disease (GVHD) with low-dose glu

215 ation (BMT) resulted in marked inhibition of acute graft-versus-host disease (GVHD) with retention of

216 topoietic cell transplantation is limited by acute graft-versus-host disease (GvHD), a severe complic

217 nces of neutrophil engraftment, grades II-IV acute graft-versus-host disease (GVHD), and chronic GVHD

218 ll IFN-gamma production correlated with more acute graft-versus-host disease (GVHD), and decreased KI

219 he major cause of morbidity and mortality in acute graft-versus-host disease (GVHD), and pathological

220 teroids are the accepted primary therapy for acute graft-versus-host disease (GVHD), but durable resp

221 , with primary risk factors including severe acute graft-versus-host disease (GVHD), chronic extensiv

222 f HLA-A, B, or C, on the risks for grade 3-4 acute graft-versus-host disease (GVHD), chronic GVHD, tr

223 in improving engraftment without increasing acute graft-versus-host disease (GVHD), despite much lar

224 The incidences of grade 2 to 4 acute graft-versus-host disease (GVHD), grade 3 and 4 ac

225 ortant causes of diarrhea after HSCT include acute graft-versus-host disease (GVHD), infections, and

226 In acute graft-versus-host disease (GVHD), naive donor CD4(

227 There was no impact of EBV reactivation on acute graft-versus-host disease (GVHD), nonrelapse morta

228 ointestinal tract are major target organs of acute graft-versus-host disease (GVHD), the major compli

229 KIR-L mismatch had no effect on grade III-IV acute graft-versus-host disease (GVHD), transplantation-

230 responses of allogeneic BM donors may affect acute graft-versus-host disease (GVHD), we investigated

231 ients developed grade C (n = 4) or D (n = 1) acute graft-versus-host disease (GVHD), with only one at

232 vs steroids/placebo to treat newly diagnosed acute graft-versus-host disease (GVHD).

233 influenza virus infection and in a model of acute graft-versus-host disease (GVHD).

234 of Paneth cell loss in gastrointestinal (GI) acute graft-versus-host disease (GVHD).

235 s play a critical role in pathophysiology of acute graft-versus-host disease (GVHD).

236 y complications, predominantly infection and acute graft-versus-host disease (GVHD).

237 No validated biomarkers exist for acute graft-versus-host disease (GVHD).

238 titox in 30 patients with steroid refractory acute graft-versus-host disease (GVHD).

239 logeneic BMT without DLI and 5 patients with acute graft-versus-host disease (GVHD).

240 mmune disease that is indistinguishable from acute graft-versus-host disease (GVHD).

241 m cell transplantation can be complicated by acute graft-versus-host disease (GVHD).

242 ed with increased incidence of grades III-IV acute graft-versus-host disease (GVHD).

243 IL-18 is elevated during acute graft-versus-host disease (GVHD).

244 eneic stem cell transplantation resulting in acute graft-versus-host disease (GVHD).

245 observed between groups in the incidence of acute graft-versus-host disease (GVHD).

246 tal models of inflammatory bowel disease and acute graft-versus-host disease (GVHD).

247 ell transplantation (allo-HCT) is limited by acute graft-versus-host disease (GVHD).

248 disorders but carries a significant risk of acute graft-versus-host disease (GVHD).

249 HSCT, broad-spectrum antimicrobial use, and acute graft-versus-host disease (GVHD; adjusted odds rat

250 Thirty-eight percent of patients developed acute graft-versus-host disease (GVHD; grade II in all b

251 IR3DS1 was associated with lower-grade II-IV acute graft-versus-host disease (GVHD; odds ratio = 0.71

252 icted a greater risk of developing grade 3-4 acute graft-versus-host disease (GVHD; RR = 1.58, 95% CI

253 Acute graft-versus-host-disease (GVHD) after non-myeloab

254 In hematopoietic stem cell transplantation, acute graft-versus-host-disease (GVHD) is caused by an a

255 alyzed with respect to tempo of engraftment, acute graft-versus-host-disease (GVHD), clinical extensi

256 phyrin (CoPP) can prevent the development of acute graft-versus-host-disease (GVHD).

257 y; acute toxicity (veno-occlusive disease or acute graft versus-host disease [GvHD]); chronic GvHD; o

258 G was associated with decreased incidence of acute graft-versus-host disease (hazard ratio [HR], 0.31

259 associated with an increased risk of severe acute graft-versus-host disease (HR = 1.43, P = 0.730).

260 d mortality (HR = 1.54, 1.54), and grade 3-4 acute graft-versus-host disease (HR = 1.49, 1.77) compar

261 The CI of acute graft-versus-host disease II to IV was 32.3% after

262 neutrophil and platelets recovery and lower acute graft versus host disease (II-IV) (P<0.01).

263 ions were present in 50% of the patients and acute graft-versus-host disease in 33%.

264 and Treg cells in association with clinical acute graft-versus-host disease in allogeneic hematopoie

265 fectively suppress inflammatory responses in acute graft-versus-host disease in humans and in a numbe

266 mAb against PD-1H, which strikingly prevents acute graft-versus-host disease in semi- and fully allog

267 idence interval, 1.84-31.7), controlling for acute graft-versus-host disease, in 109 patients with Ph

268 h in vitro and in vivo, including inhibiting acute graft-versus-host disease induced by allogeneic CD

269 he role of IL-18 in three disease processes (acute graft-versus-host disease, insulin-dependent diabe

270 Acute graft-versus-host disease is a complication that a

271 Acute graft-versus-host disease is one of the commonest

272 c graft-versus-host disease (cGVHD) and late acute graft-versus-host disease (L-aGVHD) are understudi

273 impact in vivo alloresponses using a severe acute graft versus host disease model.

274 bit potent regulatory function in vivo in an acute graft-versus-host disease model.

275 Five patients had grade II or grade III acute graft-versus-host disease; none had extensive chro

276 required no platelet or RBC transfusion, and acute graft-versus-host disease of greater than grade 2

277 ppeared to be independent of CMV viral load, acute graft-versus-host disease, or ganciclovir-associat

278 , reduced-intensity conditioning (P = 0.02), acute graft-versus-host disease (P = 0.03), and chronic

279 matched HCT, myeloablative conditioning, and acute graft-versus-host disease (P values < .01).

280 aper, we show human CD4/CD8 double-positive, acute graft-versus-host disease-protective, minor H Ag-s

281 Acute graft-versus-host disease rates were similar betwe

282 survival or in the incidence or severity of acute graft-versus-host disease regardless of exposure t

283 Grade II to IV acute graft-versus-host disease related to steroid treat

284 Grade 2 to 4 acute graft-versus-host disease risks were higher after

285 rse diseases(1), including steroid-resistant acute graft versus host disease (SR-aGvHD)(2).

286 Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) poses one of

287 Therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains subop

288 rominent among patients who developed severe acute graft-versus-host disease, suggesting that short t

289 Only 1 patient developed skin-only acute graft-versus-host disease that resolved without an

290 the armamentarium against steroid-refractory acute graft-versus-host disease, the prognosis of this e

291 History of grade II-IV acute graft versus host disease was associated with an i

292 The probability of grade 2-4 and 3-4 acute graft-versus-host disease was 0.49 (95% CI, 0.38-0

293 The cumulative incidence of grade III to IV acute graft-versus-host disease was 36% by D+100.

294 Acute graft-versus-host disease was associated with fewe

295 serum level of cyclosporine, infections, and acute graft versus host disease were compared statistica

296 abilities of nonrelapse mortality and severe acute graft-versus-host disease were 8% and 4%.

297 mia or myelodys-plastic syndrome, and severe acute graft-versus-host disease were associated with sig

298 er risks of LONIPC, but age, graft type, and acute graft-versus-host disease were not identified as r

299 lymphocyte count <300 cells/uL at D +30, and acute graft-versus-host disease were predictors of ADV v

300 Survival, engraftment, and acute graft-versus-host disease were studied.